Ozomet-G1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients whose blood glucose levels are inadequately controlled by diet and exercise alone. Glimepiride, a sulfonylurea class agent, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, contributing to better glycemic control. The extended-release formulation allows for a gradual release of the active ingredients, promoting sustained plasma concentrations, minimizing gastrointestinal side effects commonly associated with metformin, and enhancing patient compliance through once-daily dosing. Ozomet-G1 Tablet ER should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to its components. Caution is advised in patients with hepatic dysfunction or cardiovascular disease. Regular monitoring of renal function and blood glucose is recommended during therapy to ensure safety and efficacy.